Page last updated: 2024-12-06

oxdralazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Oxdralazine is a drug that acts as a vasodilator, specifically by relaxing smooth muscle in blood vessels. Its mechanism of action involves inhibiting the enzyme phosphodiesterase, which leads to an increase in cyclic GMP levels, promoting vasodilation. Oxdralazine has shown promising results in preclinical studies for treating hypertension, heart failure, and pulmonary hypertension. Its potential benefits include lowering blood pressure, reducing cardiac workload, and improving blood flow to the lungs. However, oxdralazine has not yet been approved for clinical use in humans due to concerns about potential side effects, such as hypotension and dizziness. Current research efforts are focused on optimizing the pharmacokinetic profile and therapeutic window of oxdralazine to minimize side effects and enhance its clinical efficacy. Further investigation is needed to determine its long-term safety and effectiveness in humans.'

oxdralazine: RN & N1 given for parent; oxdralazine, L-6150, & DL 150 IT are for di-HCl; hydrazinopyridazine is used as shortened name for this cpd; named as 3-hydrazino- or 6-hydrazino- depending on which numbering system used; RN given refers to parent cpd; structure in Negwer, 5th ed, #862 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28434
CHEMBL ID2104718
SCHEMBL ID2109389
MeSH IDM0048468

Synonyms (21)

Synonym
oxdralazine
l 6150
oxdralazine [inn]
2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol
2,2'-((6-hydrazino-3-pyridazinyl)imino)diethanol
oxdralazina
oxdralazinum
unii-k6su81c9v1
oxdralazinum [inn-latin]
6-(bis(2-hydroxyethyl)amino)-3(2h)-pyridazinone, hydrazone
k6su81c9v1 ,
17259-75-5
oxdralazina [inn-spanish]
dl 150
CHEMBL2104718
SCHEMBL2109389
DTXSID30169351
2,2'-((6-hydrazinylpyridazin-3-yl)azanediyl)diethanol
(z)-2,2'-((6-hydrazono-1,6-dihydropyridazin-3-yl)azanediyl)diethanol
Q27282027
2-[(6-hydrazinylpyridazin-3-yl)(2-hydroxyethyl)amino]ethan-1-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The double regimen caused a drop in pressure of 16/11 mm Hg after one month (daily doses 25 mg chlorthalidone, 103 +/- 25 mg propranolol), and this reduction did not change at the third month in spite of dosage increases (daily doses 25 mg chlorthalidone, 222 +/- 77 mg propranolol)."( A crossover trial of oxdralazine in hypertension.
Criscuolo, D; Galli, F; Salvadeo, A; Segagni, S; Villa, G, 1983
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]